Firebrick Pharma Ltd
ASX:FRE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
AU |
Intrinsic Value
The intrinsic value of Firebrick Pharma Ltd (FRE) under the Base Case is 0.004 AUD per share. Compared with the current market price of 0.03 AUD, the stock appears Overvalued by 86% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Firebrick Pharma Does
Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold.
- Headquarters
- Australia AU
- IPO date
- Jan 28, 2022
Earnings Waterfall
Firebrick Pharma Ltd
The intrinsic value for Firebrick Pharma Ltd (FRE) under the Base Case is 0.004 AUD.
Compared with the current market price of 0.03 AUD, the stock appears Overvalued by 86% .